New research presented at the EULAR 2025 Congress provides updated real-world data on cancer and cardiovascular risks associated with Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis. The findings indicate that JAKi did not significantly increase overall cancer incidence compared with other biologics, but there is an elevated risk of developing keratinocyte cancer, especially basal cell carcinoma. Additionally, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer cardiovascular benefits, though further research is required to confirm these findings.

Source: EULAR